Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of USL255 adjunctive therapy for refractory partial-onset seizures
2009-016996-31Phase 3Completed
- Sponsor
- Upsher-Smith Laboratories
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in focal-onset epileptic seizures and Focal Onset Epilepsy comparing USL255 adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Primary efficacy end point. Started Apr 2010; status: completed.
02
Drugs
topiramate
03
Conditions
focal-onset epileptic seizuresFocal Onset Epilepsy
Beyond the preview
Go deeper on 2009-016996-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016996-31.